Endo International (NASDAQ:ENDP) (TSE:ENL) had its price objective reduced by Canaccord Genuity from $17.00 to $15.00 in a research note released on Wednesday morning, The Fly reports. They currently have a buy rating on the stock.
ENDP has been the topic of several other reports. Svb Leerink cut shares of Endo International from an outperform rating to a market perform rating in a research report on Tuesday, March 5th. Zacks Investment Research cut shares of Endo International from a hold rating to a strong sell rating in a research report on Tuesday, April 30th. Piper Jaffray Companies reaffirmed a hold rating on shares of Endo International in a research report on Friday, March 1st. ValuEngine raised shares of Endo International from a sell rating to a hold rating in a research report on Monday, February 4th. Finally, SunTrust Banks initiated coverage on shares of Endo International in a research report on Tuesday, March 19th. They set a buy rating and a $13.00 price target on the stock. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $14.88.
Shares of ENDP traded down $0.08 during mid-day trading on Wednesday, hitting $6.52. The company had a trading volume of 2,710,859 shares, compared to its average volume of 3,359,877. Endo International has a 1-year low of $5.92 and a 1-year high of $18.50. The stock has a market capitalization of $1.47 billion, a PE ratio of 2.37 and a beta of 1.12.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Thursday, May 9th. The company reported $0.53 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.11. Endo International had a negative net margin of 18.35% and a negative return on equity of 199.18%. The business had revenue of $720.00 million for the quarter, compared to analysts’ expectations of $692.31 million. During the same period last year, the company earned $0.67 earnings per share. The company’s quarterly revenue was up 2.9% on a year-over-year basis. On average, research analysts expect that Endo International will post 2.18 earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp raised its stake in Endo International by 2.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,513,250 shares of the company’s stock valued at $42,299,000 after buying an additional 66,398 shares during the last quarter. Neuberger Berman Group LLC purchased a new stake in shares of Endo International in the 3rd quarter worth $202,000. Bowling Portfolio Management LLC purchased a new stake in shares of Endo International in the 4th quarter worth $914,000. First Quadrant L P CA purchased a new stake in shares of Endo International in the 4th quarter worth $92,000. Finally, Arizona State Retirement System increased its stake in shares of Endo International by 6.4% in the 4th quarter. Arizona State Retirement System now owns 307,485 shares of the company’s stock worth $2,245,000 after purchasing an additional 18,374 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors and hedge funds.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Article: Trading Options- What is a Strangle?
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.